#AHA19 – [Abstract Only] Randomized Trial: An Antiplatelet-based Strategy is Associated with Better Outcomes vs. Anticoagulation After Transcatheter Aortic-Valve Replacement

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: GALILEO Trial Finds Higher Risk of Death, Bleeding With Rivaroxaban After TAVR – American College of Cardiology (free) AND Global Study Comparing a Rivaroxaban-based Antithrombotic Strategy to an Antiplatelet-based Strategy After TAVR – GALILEO – American College of Cardiology (free) AND GALILEO: Rivaroxaban-Based Antithrombotic Strategy or Antiplatelet-Based Strategy After TAVR? – Docwire (free)

#AHA19 – Just Presented at the 2019 American Heart Association Annual Meeting

Related Commentary on Twitter

Patients who had had successful TAVR randomized to either a rivaroxaban-based antithrombotic regimen or an antiplatelet-based regimen. At 17 mos, death or thromboembolic complications occurred more frequently w/ rivaroxaban. See the GALILEO trial. #AHA19 https://t.co/boQo9SbGKe

— NEJM (@NEJM) November 16, 2019